艾昆纬-中东与非洲医药市场季刊 Middle East Africa Pharmaceutical Business Insights 202501

MiddleEast&Africa

PharmaceuticalBusinessInsights

Thirty-FourthEdition

ReportReleaseDate:Jan2025

AnalyticalTimeframe:MATSep2024

©2025.Allrightsreserved.IQVIA®isaregisteredtrademarkofIQVIAInc.intheUnitedStates,theEuropeanUnion,andvariousothercountries.

Disclaimer

IQVIAisnotan“authorisedperson”forthepurposesoftheFinancialServicesandMarketsAct2000(“FSMA”)anddoesnotprovideinvestmentadviceorcarryonanyotherregulatedactivityunderPartIIoftheFSMA2000(RegulatedActivities)Order2001

Theforecasts,projections,andrelatedinformationcontainedhereinaremadeandprovidedsubjecttotheassumptions,methodologies,caveats,andvariablesdescribedinthisreportandarebasedonthirdpartysourcesanddatareasonablybelievedtobereliable.No

warrantyismadeastothecompletenessoraccuracyofsuchthirdpartysourcesordata

Thisreport,inpartorinwhole,isnotintendedtoconstituteinvestmentadvice,andisnotarecommendationtopurchaseornotpurchase,anendorsementof,oranopinionastothevalueof,anysecurityoranyinvestmentinstrumentofanyentity

Aswithanyattempttoestimatefutureevents,theforecasts,projections,conclusions,andotherinformationincludedhereinaresubjecttocertainrisksanduncertainties,andarenottobeconsideredguaranteesofanyparticularoutcome

Thisreportshallnotbepublished,norshallanypublicreferencestoIQVIAbemaderegardingtheseservicesorthisreport,withoutIQVIA’priorwrittenapproval.Whensoprovided,thisreportandtheinformationhereinmustalwaysbeprovidedandusedinitsentirety,includingthiscompleteDisclaimerpage

ThisreportissubjecttotheIQVIAGeneralTermsandConditions.

IQVIA1

Agenda

+Newsletterreportsummary

+Regionalsummaryandanalysis+Spotlightonnewoffering

+Appendix

IQVIA

2

BusinessinsightssnapshotMATQ32024:Manycountrieshavewitnessed

highgrowthin2024

+9.6%

+12.2%

33.9

1.0

0.30.4

0.30.40.9

30.2

1.6

1.7

1.8

1.5

1.6

0.30.70.81.2

2.6

23.5

1.7

2.4

3.54.0

4.5

1.2

2.93.4

3.9

11.2

1.2

1.8

2.3

2.53.1

8.5

12.4

202020232024

LEBANONJORDANTUNISIA

MOROCCOKUWAIT

FR.WESTAFRICA

ALGERIAS.AFRICAEGYPT

UAE

SAUDIARABIA

•SaudiArabialeadstheMEAregionat$12.4Binvalue,expandedat11.1%PPGinvalueterms

•UAEfollowsasthe2ndlargest,with$4.5Binvaluehasseenagrowthof17.5%PPGand15.8%

CAGR2

MATQ3

•Overall,MEAPharmaceuticalBusinesshasreached$33.9Bvalueand8.7BUnits

•Valuesalesgrowthhasbeenat12.2%PPG1(PreviousPeriodGrowth)and9.6%CAGR2whileVolumesaleshasdeclinedat-0.7%PPG&increased

at1.6%CAGR2

•RetailchanneldominatestheMEARegionwith68.9%($23.3B)shareinvaluesaleswith13.9%PPGand81.8%(7.0BUnits)shareinvolumewith1.1%PPG

•GrowthofHospitalchannelhasincreasedintermsofPPG8.6%invalueanddecreasedby-8.1%PPGinvolume

•MNCsleadwith59%shareintotalvaluesaleswith11.6%PPG

•Localcompanieshavegrownat13.1%PPGinvalueand-0.8%PPGinvolume

•NovartisSanofiandGSKcontinuetobethetopcorporationsinMEA

•Amongstthetop10corporation,EliLillyisthefastestgrowingcorporationgrowingat100.6%PPG

•AlimentaryTract,MetabolismisthetopTAholding20.3%ofvaluesharewiththehighestcontributioninKSA(37.4%)

1.PPG:PreviousPeriodGrowth:MATQ32024vs.MATQ32023growth

2.CAGR:CompoundAnnualGrowthRatefortheperiodMATQ32020toMATQ32024;

Source:IQVIAAuditedData,MATQ32024,includesIQVIAprivate,LPO,Institutionaldatawhereavailable;

Valuesalesatex-factorypricelevelwithoutdiscount;Allsalesareatconstantexchangerateanddon’taccountforanycurrencyfluctuationordevaluation©2025.Allrightsreserved.

IQVIA3

Amongthekeycountries,KSAsawgrowthof11.1%andcontinuestolead,

accountingfor36.7%ofsalesinMEARegion

UnitedArab

Emirates(UAE)

•UAEgrewby17.5.%PPG(fastestgrowingcountryinMEAregion**)accountingfor$4.5Bsales

•Top10TAsaccountfor50.3%oftotalsales,whereinNewerGenTypeIIAntidiabeticsTAisgrowingat61.1%PPG

•Top10corporationsaccountfor49.2%shareinsaleswithEliLillybeingthefastestgrowingat83.8%PPG;mainlydrivenbytopbrandslikeMounjaro(146.4%),Cialis(7.2),andTaltz

(20.8%)onPPG

SaudiArabia(KSA)

•SaudiArabiahasgrownby11.1%PPG,makingitthesecondfastestgrowingcountryinMEA,withsalesvaluedat$12.4B

•Hospitalchannelgrewby5%PPGandaccountingfor48.4%oftotalmarketsales

•Top10corporationsaccountfor45.1%shareinsales.HikmaPharmaisleadingwith6.3%shareand4.1%PPG

•JamjoomPharma(27.1%PPG)isthefastestgrowingLocal/RegmainlydrivenbytopbrandslikeAzi-Once(72.8%),VitaminD3(17.9%),Hyfresh(52.0%)andRelaxon(51.8%)onPPG

10.3%

13.4%

11.9%

36.7%

SouthAfrica1

•SouthAfricahasgrownby1.6%PPGaccountingfor$3.5Bsaleswiththeretailchannelaccountingfor82.3%of

totalsales

•Cough&ColdPreparationsTAcontinuestobeTopTAat-0.9%PPGand6.4%share

•Top10corporationsaccountfor52.1%shareinsales.

AdcockIngram,alocalfirm,isleadingwith9.4%shareandCiplabeingthefastestgrowingat9.9%PPG

Egypt(EGY)*

•Egypthasdeclinedby-5.5%PPGdrivenbygrowthfromRetailchannel(-0.5%PPG)accountingfor81.7%of

country’sUnitssales

•SystemicAntibacterialsisthetopTAinEgyptwith10.7%UnitssharewhileAntihypertensives(0.3%PPG)isthe

fastestgrowingamongstthetop10TAs

•Top10corporationsaccountfor43.5%shareinvolumesales,Pharcoisleadingthemarketwith7.6%shareandSanofiisthefastestgrowingcorporation(19.1%PPG)

Source:IQVIAAuditedData,MATQ32024,includesIQVIAprivate,LPO,Institutionaldatawhereavailable;Valuesalesatex-factorypricelevelwithoutdiscount;Egyptsalesatconstantexchangerateanddon’taccountforanycurrencyfluctuationordevaluation

Note1:SouthAfricaRetailincludesdatafromDistributors,Wholesalers,DirectsalesfromManufacturers,Buyinggroupscoveringnearly86%ofthemarket,excludingPublicHospitals.|OverallSouthAfricamarketincludesRetailandStateSectordata|GrowthinStateSectorincludesdirecttostatedeliveries,retrospectivedataadditionandsomedirectbuyoutsfromStateHospitalsin2019-2020

*inEgypt,weupdatedtheinsightsbasedonsalesunits;Egyptmarketgrewby39.8%PPGintermsofsalevalue;**ExcludingEgyptandLebanon

©2025.Allrightsreserved.

IQVI

4

AlgeriabusinessinMEAisgrowingat7.3%PPGmainlydrivenby

local/regionalplayerswith13.5%PPG

Algeria(ALG)

•Algeriaretailchannelsalesincreasedby7.3%PPGaccountingfor$2.6BsalesinMATQ32024period

•TopTAsforAlgeriaareAntihypertensives(9.6%PPG)and

Insulin&Analogs(-5.3%PPG).LipidRegulatorsisthefastestgrowingTAat13.5%PPGamongstthetop10TAs

•MSPharmaisthetopcorporationinAlgeriawith7.3%of

marketshareandisthefastestgrowingcompanyamongstthetop10at14.7%PPG

•AmongstthetopproductsofMSPharmalikeExval(26.8%PPG),Arovan(5.4%PPG),andUnirox(10.4%PPG)

Morocco(MOR)

•Moroccoretailchannelhasincreasedby8.6%CAGRand5.6%PPGaccountingfor$1.6BsalesinMATQ32024

•ThisincreaseinsalesismainlyattributedtoLocalcorpsthathavegrownby8.3%.MNCsthathavegrownby3.3%PPG

whileaccountingfor52%oftotalsales

•Amongstthetop10corporations,BottuSAcontinuestolead,with5.8%shareinMATQ32024.Laprophanisthefastest

growingamongsttop10at25.4%PPG

•AmongstthetopproductsofLaprophan,Ixor(PPG39.5%),

Neofortan(PPG51.0%)andFloxam(PPG27.9%);thesearecontributingto25%valuesalesinMATQ32024

5.2%

7.6%

4.8%

4.9%

FWA

Fr.WestAfrica(FWA)

•FWAretailchannelhasgrownby5.5%PPGaccountingfor$1.8BsalesinMATQ32024

•Local/Regionalplayersgrewby9.6%PPGwhileaccountingfor49%oftotalsales

•Amongstthetop10corporations,Sanoficontinuestobethetopsellingcorporationwith6.4%sharewhilePharma5isthefastestgrowingtopcorporationat16.1%PPGamongstthetop10corporations.

•Pharma5growthisdrivenbytopproductslikeAclav(17.9%PPG),Astaph(28.9%PPG)andNuravit(7.7%PPG)

Kuwait(KWT)

•Kuwaitsalesincreasedby4.0%PPGaccountingfor$1.7BsalesdrivenbyLPOchannelwith74.7%contributionoftotalsales

•Top10corporationsaccountfor56.2%shareinsaleswith

Novartisleadingthebusinesswith8.2%shareandincreasedby38.8%PPGanditisthe2ndfastestgrowingamongtop10corporationsafterEliLilly(114%PPG)

•Novartisgrowthisdrivenbyhighgrowthproductslike

Cosentyx(139.4%),Xolair(10.3%)andEntresto(31.5%)PPGandnewlauncheslikeOmnitropeandHyrimoz

Source:IQVIAAuditedData,MATQ32024,includesIQVIAprivate,LPO,Institutionaldatawhereavailable;Valuesalesatex-factorypricelevelwithoutdiscount;Allsalesareatconstantexchangerateanddon’taccountforanycurrencyfluctuationordevaluation

©2025.Allrightsreserved.

IQVI

5

Tunisiaisgrowingat9.3%PPGinMEAregion

Lebanon(LEB)*

•Lebanonretailchannelunitsalesincreasedby25.6%PPGreaching90.2MunitsalesinMATQ32024

•GSKisleadingtheLebanon,with11.3%shareand43.1%

PPGandJulpharisthefastestgrowingcorporationwith65.5%PPGamongstthetop10corporations

•Top10productsforJulpharcontribute78.7%ofthetotalUnitssalesamongstwhichAdol(56.9%),Profinal(203.4%),andAlbenda(111.4%)PPGarefastgrowingandhigh

contributingproducts

Jordan(JOR)

•Jordanretailchannelsalesincreasedby2.3%PPGaccountingfor$0.4BinMATQ32024

•Amongstthetop10TAs,NewerGenTypeIIAntidiabetesisthefastestgrowingTAwith21.6%PPG

•AlthoughHikmaisleadingthebusinesswith8.8%share,itssaleshasincreasedby1.6%inMATQ32024.NovoNordiskhasregisteredfastestgrowthof24.6%PPGamongthetop10corporations

•TopsalescontributingproductsforNovoNordiskincludesOzempic(89.3%PPG),Saxenda(-48.9%PPG)and

Norditropin(14.3%PPG)

1.0%

2.8%

1.3%

Tunisia(TUN)

•Tunisiahasgrownby9.3%PPGaccountingfor$1.0BsalesinMATQ32024;

•Retail&Hospitalchannelgrewby8.4%and11.7%PPG

respectively;Retailchannelaccountsfor71.3%oftotalsales

•Antihypertensive&SystemicAntibacterialTAsleadthemarket;bothtogetheraccountingfor16.3%shareinsales

•Mediscontinuestobetheleadingcorporationwith6.7%share.UnimedTunis(65.3%PPG)andPhiladelphiaPh.(19.2%

PPG)arethefastestgrowingcorporationsamongstthetop10players

•FastestgrowingproductsforUnimedTunisinclude

Enoxamed(361.3%),Lenticlean(21.9%)andSodChlorideUnib(137.3%)PPG

Source:IQVIAAuditedData,MATQ32024,includesIQVIAprivate,LPO,Institutionaldatawhereavailable;Valuesalesatex-factorypricelevelwithoutdiscount;Allsalesareatconstantexchangerateanddon’taccountfor

anycurrencyfluctuationordevaluation;

*duetohyperinflationsituationinLebanon,weupdatedtheinsightsbasedonsalesunits©2025.Allrightsreserved.

IQVIA

6

Agenda

+Newsletterreportsummary

+Regionalsummaryandanalysis+Spotlightonnewoffering

+Appendix

IQVIA

7

By2028,GlobalpharmabusinessisexpectedtoreachUS$2.27T;Middle

East&AfricapharmabusinesscollectivelytobeUS$63.3B

HighlightsofIQVIAMarketPrognosis2024-2028(Sep2024)

Russia&CIS

•Size(2028):US$37B

•CAGR’23-28’:6.8%

GlobalMarket

Size(2028):$2.27TCAGR’23-28’:7.4%

Europe

•Size(2028):US$478B

•CAGR’23-28’:7.5%

NorthAmerica

•Size(2028):US$1,147B

•CAGR’23-28’:8.2%

MiddleEast

•Size(2028):US$36B

•CAGR’23-28’:7.7%

Japan

•Size(2028):US$69B

•CAGR’23-28’:0.9%

SouthEast&EastAsia

•Size(2028):US$259B

•CAGR’23-28’:3.6%

Africa

•Size(2028):US$28B

•CAGR’23-28’:5.7%

IndianSubcontinent

•Size(2028):US$54B

•CAGR’23-28’:9.4%

Pharmerging

•Size(2028):US$406B

•CAGR’23-28’:7.5%

LatinAmerica&Carrib.

•Size(2028):US$147B

•CAGR’23-28’:14.3%

MajorDeveloped

•Size(2028):US$1,509B

•CAGR’23-28’:7.3%

Oceania

•Size(2028):US$20B

•CAGR’23-28’:3.3%

Note–Sizeindicates2028SalesinLC$

Source:IQVIAMarketPrognosis2024-2028(Sep2024);IQVIAMarketPrognosisGlobalsummarizesthekeypointsfromeachoftheRegionalstudiesandaddsthistodeskresearchconductedinsevenotherregions.AcombinationofIQVIA,officialimport/exportandlocalmanufacturerfiguresareusedtocompilethisreportandestablisheventsthatcouldimpactthesalesforecastovertheperiodreviewed

©2025.Allrightsreserved.

8

MiddleEast&Africapharmabusinessisforecastedtoreach~USD49Bin

ValueSalesbyCountry(Historicalvs.Forecasted)

LC$B(2018-2028F)

33

31

2,275

+7.4%

69

259

249

38

9429

67

478

450

1,188/20

\2060\2551

189

191

171

279

258

232

1,079

936

853

575

1,73218

41\

108

68

230

-27

23

239

14

1,22920-19

13

222

13

1,11120

62\

62

204

420

——18

\18

389

17

\16

62\2346

362

60\21

42

246

1,147

1,003

621

550

519

20

36

28

37

20

33

26

35

2,145

/

50\

134

54

19

31

25

2,005

/

45\

121

68

147

69

19

29

24

1,875

17 25-21 2734

+7.5%

1,591

17

23

23

25

32

1,443

14

75

66

217

1,340/22

22

24

29

67

64

207

334

304

775

682

2018201920202021202220232024F2025F2026F2027F2028F

2024andiscollectivelygrowingat4.3%(2018through2023)

Growthsummary(Historicvs.Forecasted)

Regions

CAGR’18-’23

CAGR‘23-’28

Oceania

6.6%

3.3%

MiddleEast

4.1%

7.7%

Africa

4.5%

5.7%

CIS

11.1%

6.8%

IndianSub-Continent

10.1%

9.4%

LatinAmerica,includingtheCaribbean

12.3%

14.3%

Japan

1.7%

0.9%

South-East&EastAsia

4.9%

3.6%

Europe

7.6%

7.5%

NorthAmerica

8.3%

8.2%

GlobalPharmaBusiness

7.5%

7.4%

Growth>=GlobalGrowth<Global

Source:IQVIAMarketPrognosis2024-2028(Sep2024)andex-Mfg.sales,LC$;IQVIAMarketPrognosisGlobalsummarizesthekeypointsfromeachoftheRegionalstudiesandaddsthistodeskresearchconductedinsevenotherregions.AcombinationofIQVIA,officialimport/exportandlocalmanufacturerfiguresareusedtocompilethisreportandestablisheventsthatcouldimpactthesalesforecastovertheperiodreviewed

©2025.Allrightsreserved.

IQVI

9

BothchannelsgrewintheirvaluegrowthinPPGwithretailgrowingthe

fastestat13.9%PPGcontributing68.9%oftotalvalueofMEAbusiness

MiddleEast&Africa

Totalsales(USD,B)

Totalsales(Units,B)

+9.6%

+1.6%

-0.7%

+12.2%

33.87

30.18

31%

69%

26.94

8.148.278.698.728.66

24.89

32%

68%

23.50

31%

30%

70%

32%

68%

69%

21%

19%

19%

20%

18%

79%

81%

81%

80%

82%

2020

202120222023

2024

PPG%¹

CAGR%¹

Hospital

8.6%

9.1%

Retail

13.9%

9.8%

Total

12.2%

9.6%

20202021202220232024

PPG%¹

CAGR%¹

Hospital

-8.1%

-1.4%

Retail

1.1%

2.3%

Total

-0.7%

1.6%

•Retailisthedominantchannelintheregionaccountingfor68.9%valuesalesintheregion

•HospitalchannelcontinuestohaveastablevaluegrowthintheregionwithUAE,Kuwait&KSAgrowingby18.6%,2.0%&5.0%PPGrespectively

•ThegrowthofretailchannelcanbemajorlyattributedtoexpandingsizeofoverallbusinessinMEA

1.PPG(PreviousPeriodGrowth)calculatedforMATQ32024vs.MATQ32023andCAGR(CompoundAnnualGrowthRate)iscalculatedforMATQ32020-2024Note:Retailincludesprivatehospitalsandisavailableforallcountriesincluded

AnalysisbasedonAlgeria,Egypt,Fr.WestAfrica,Jordan,Kuwait,Lebanon,Morocco,SaudiArabia,SouthAfrica,Tunisia,UAE

Source:IQVIAAuditedData,MATQ32024,includesIQVIAprivate,LPO,Institutionaldatawhereavailable;Valuesalesatex-factorypricelevelwithoutdiscount;Egyptsalesatconstantexchangerateanddon’taccountforanycurrencyfluctuationordevaluation

IQVI

10

©2025.Allrightsreserved.

Shareoflocal/regionalcompaniescontinuestogrowinvalueterms,

howeverMNCstillcontrolshighershareinMEA

MiddleEast&Africa

Hikma,Tabuk&SpimacoareamongthelargestLocal/Regionalcompaniesin

Collectivelytheygeneratevaluesalesof$2.5Bandcontribute18.1%ofthe

totalsalesgeneratedbyLocal/RegionalplayersinMEA

Totalsales(USD,B)

+9.6%

+12.2%

30.1833.87

23.5024.8926.94

PPG%

CAGR%

LOC/REG¹

13.1%

11.9%

MNC¹

11.6%

8.1%

Total

12.2%

9.6%

37.7%39.0%40.3%40.7%41.0%

PPG%

CAGR%

LOC/REG1

-0.8%

2.4%

MNC1

-0.3%

0.0%

Total

-0.7%

1.6%

62.3%61.0%59.7%59.3%59.0%

20202021202220232024

Totalsales(Units,B)

+1.6%

-0.7%

8.148.278.698.728.66

66.1%

67.0%

68.0%

68.3%

68.2%

33.9%

33.0%

32.0%

31.7%

31.8%

20202021202220232024

•GrowthofLocalcompaniesintheregionwasmainlyreflectedinUAE(14.8%),Algeria(13.5%)andTunisia(12.6%)PPG

•GrowthofMNCcompaniesmainlyreflectedinUAE(18.2%),SaudiArabia(10.6%)andTunisia(6.1%)PPG

1.MNC:Multinationalcompanies,Loc/Reg:LocalandRegionalcompanies

Source:IQVIAAuditedData,MATQ32024,includesIQVIAprivate,LPO,Institutionaldatawhereavailable;Valuesalesatex-factorypricelevelwithoutdiscount;Egyptsalesatconstantexchangerateanddon’taccountfor

IQVIA

11

anycurrencyfluctuationordevaluation©2025.Allrightsreserved.

MostMEAcountrieshavecontinuedtogrowinvaluesalesinMATQ3

MiddleEast&Africa

Totalsales(USD,B)

Total

33.9

8.78.78.7

8.18.3

30.2

•UAE,KSAand

TunisiaareamongthefastestgrowinginMEAregionin

termsofvaluessales

•Valuegrowthin

UAE(17.5%PPG)

Hospitalchannelgrowth(18.6%)ishighcomparedtoretailchannel

growth(17.1%)

•VolumegrowthinUAEismainly

drivenbyLocalplayerswith

10.2%

sales(Units,B)

0.1

0.80.1

0.90.2

1.00.3

3.6

0.5

0.7

0.40.60.1

0.10.10.10.20.3

0.10.10.10.20.3

0.10.10.10.20.3

0.4

0.5

0.4

0.7

1.1

3.7

0.91.1

1.01.1

1.01.1

4.0

0.9

0.3

3.9

3.8

0.8

0.9

0.7

0.5

0.9

0.9

0.30.40.91.5

0.40.50.81.31.5

0.30.41.01.6

0.10.10.10.3

1.7

26.9

0.40.70.91.3

1.8

24.9

2.6

1.7

0.81.21.21.2

3.5

2.4

1.32.1

2.9

1.5

2.9

2.4

1.42.4

3.1

4.04.5

12.4

2.4

1.82.5

3.43.9

11.2

2.3

3.1

3.2

3.3

9.6

8.5

8.4

0.3

23.50.7

1.6

20202021202220232024

PPG

CAGR

R:I¹

L:M¹

KSA

4.2%

5.1%

71:29

61:39

UAE

4.2%

8.3%

86:14

45:55

EGY

-5.5%

-0.7%

82:18

75:25

RSA

1.4%

-1.1%

55:45

81:19

ALG

4.5%

2.0%

100:0

69:31

FWA

3.6%

9.8%

100:0

53:47

KWT

-6.6%

3.5%

43:57

31:69

MOR

1.7%

5.7%

100:0

57:43

TUN

0.3%

3.7%

86:14

59:41

JOR

-3.6%

4.1%

100:0

56:44

LEB

25.6%

-7.8%

100:0

53:47

Total

-0.7%

1.6%

82:18

68:32

20202021202220232024

PPG

CAGR

R:I¹

L:M¹

KSA

11.1%

9.9%

52:48

36:64

UAE

17.5%

15.8%

75:25

20:80

EGY

39.8%

22.8%

69:31

53:47

RSA

1.6%

3.3%

82:18

57:43

ALG

7.3%

3.5%

100:0

63:37

FWA

5.5%

11.1%

100:0

49:51

KWT

4.0%

7.7%

25:75

13:87

MOR

5.6%

8.6%

100:0

48:52

TUN

9.3%

9.1%

71:29

50:50

JOR

2.3%

6.0%

100:0

47:53

LEB

23.4%

-18.6%

100:0

46:54

Total

12.2%

9.6%

69:31

41:59

1.R:IrepresentsRetailvs.Institutionalsales;L:MrepresentsLocalvs.MNCsales

AnalysisbasedonAlgeria,Egypt,Fr.WestAfrica,Jordan,Kuwait,Lebanon,Morocco,SaudiArabia,SouthAfrica,Tunisia,UAE;Source:IQVIAAuditedData,MATQ32024,includesIQVIAprivate,LPO,Institutionaldatawhereavailable;Valuesalesatex-factorypricelevelwithoutdiscount;Egyptsalesatconstantexchangerateanddon’taccountforanycurrencyfluctuationordevaluation

©2025.Allrightsreserved.

12

Alimentarytracttreatmentproductsisthelargest&fastestgrowingTA;

MiddleEast&Africa

TopsellingTherapyAreas(ATC1s)

•Alimentarytract

productscontinuestobetheleadingTAin

MEAregion

accountingfor20.3%theregionsales

•KSAaccountsfor

37.4%shareintotal

AlimentarytractsalesinMEA,whilerecordinggrowthof28.2%PPG

invalue

•Blood+B.Forming

Organshasgrownat17.7%PPG,where

48.5%oftotalTAMEAsalescontributedby

KSAandUAEgrowingataPPGof14.1%&

13.4%respectivelyinthisTA

Blood+B.FormingOrgansis2ndfastestgrowingTAamongtopTAs

PPG%

CAGR%

Rankingchange

Sales(USD,B)MATQ32024

R:I

L:M

20.9%

11.7%

1

A(ALIMENTARYTRACT,METABOL)

6.9

78:22

35:65

2.5%

7.5%

2

J(SYSTEMICANTI-INFECTIVES)

4.3

56:44

51:49

8.1%

8.3%

3

N(NERVOUSSYSTEM)

3.5

71:29

45:55

15.5%

14.3%

4

L(ANTINEOPLAST+IMMUNOMODUL)

3.4

28:72

14:86

9.0%

6.0%

5

C(CARDIOVASCULARSYSTEM)

2.9

74:26

48:52

6.1%

9.7%

6

R(RESPIRATORYSYSTEM)

2.5

84:16

51:49

17.7%

9.6%

7

B(BLOOD+B.FORMINGORGANS)1.8

51:49

36:64

12.1%

9.3%

8

M(MUSCULO-SKELETALSYSTEM)1.6

84:16

57:43

14.5%

9.0%

1

9

G(G.U.SYSTEM&SEXHORMONS)1.6

89:11

52:48

11.2%

10.1%

-1

10

D(DERMATOLOGICALS)1.5

85:15

44:56

1.R:IstandsforRetail:InstitutionandL:MstandsforLocal:MNC;InstitutionincludesLPOtenderdatawhereavailable

2.Arrowsindicatechangeincompaniesrankinginreferencetoitsrankinginthepreviousyear(MATQ32023vs.MATQ32024)AnalysisbasedonAlgeria,Egypt,Fr.WestAfrica,Jordan,Kuwait,Lebanon,Morocco,SaudiArabia,SouthAfrica,Tunisia,UAE

Source:IQVIAAuditedData,MATQ32024,includesIQVIAprivate,LPO,Institutionaldatawhereavailable;Valuesalesatex-factorypricelevelwithoutdiscount;Egyptsalesatconstantexchangerateanddon’taccountforanycurrencyfluctuationordevaluation

IQVI

13

©2025.Allrightsreserved.

Agenda

+Newsletterreportsummary

+Regionalsummaryandanalysis+Spotlightonnewoffering

+Appendix

IQVIA

14

NumberofcollaboratingdatasuppliersintheMEcountries

Morethan200collaboratingDataSuppliersintheMEregioncovering7countriessince1971

17

Kuwait

52

Egypt

8

Bahrain

38

SaudiArabia

25

UAE

Total212

in

MiddleEast

Oman(new)

Comingsoon

38

Jordan

27

Lebanon

Qatar(Launched)

InQ22024

15

©2025.Allrightsreserved.

IQVIAMEDataCoverage

Morethan200collaboratingDataSuppliersintheMEregioncovering9countries

98%actual

Egypt

98%actual

SaudiArabia

98%actual

UAE

85%actual

Jordan

85%actual

Lebanon

95%actual

Kuwait

75%coverage

Bahrain

MiddleEast

Iraq(new)

Incollaboration

withAMSAnalytix

Oman(new)

Comingsoon

Qatar(Launched)

InQ22024

©2025.Allrightsreserved.

IQVIA16

IraqPharmaceuticalMarket

ProvidingastrategicviewoftheIraqRetailmarkettodrivestrategyandbusinessinsights

Sell-inData

65%collectedasactual(censes)salesfrom35collaborating

distributors/supplierstopharmacies,inadditionto35%projecteddata

from400pharmacies

18Governorates

National,Regional&

Territorial

•Baghdad

•Kurdistan

•Center

•FuratAwsat

•South

•North

©2025.Allrightsreserved.

AuditavailableinFlexview

Attributes

4LevelsofATC

Classification

Manufacturer

ProductNFC

Pack

Measures

Productformclassification

BackData

availablefromJan2022

Sectors

Coverallproductssoldwithinpharmacies

Frequency

Theauditisreleasedonaquarterlybasis

UnitandValueSales

PriceLevel

Tradeprice

IQVIA

NewOffering

17

ESWT:Egyptswitchtracker

NewOfferings

LaunchJan-2024

Sample/TimeFrame:

•Sampleof400pharmacies

(Individual/streetph)

Methodology:

•Gatheringinputfromsample

distributedthrough4regions

(Cairo/Giza–Delta-UpperEgypt-Alexandria)

•Datacollectedin2waves/year

•Reportswillbepublishedsemesterbasis.

potentialpharmacies.

•RecordalldetailsregardingspecificTherapyAreasfor7consecutivedaysthoughadigitalplatform

•Country:Egypt

•Launchnewsyndicatedofferingswhichtarget

pharmacies’behavior

withintheirpharmacies.

•TheDispensingsplit%ofmybrand(OTC/RX)

•TheSwitchrate%ofmybrandvsthecompetitors

•PharmacistRole:Thereasonbehindtheswitches

•Whoarethemaincompetitors;“switchedto”

•Regionalperformanceforswitches

ProjectScope:

Deliverables/KPI:

©2025.Allrightsreserved.

IQVIA18

SSS:SubnationalsectorsplitFlexview

NewOfferings

LaunchQ1-2024

Duetomarketdynamics,IQVIAEgyptlaunchnewstructureforterritorialdata.

Nowyoucanhavedeeperinsightfulanalysisthroughsplitofexistingterritorialdatatomoregranularlevelofmainchannels:Individual

Pharmacies,ChainPharmacies,StoresandPrivateHospitals.

©2025.Allrightsreserved.

Frequency

Allproductssoldto

consumersarerecordedintheauditandreleased

monthly

National

•NationalLevel

LaunchDate

•Q1-2024

Jordanconsumerselloutdata

JordanSellOutDatacoversallsalestransactionalchannelfrompharmaciestoendpatient/consumer.Collectedelectronicallyfrom400PharmaciesacrossJordanwithofbackData.

~10,000+SKU’sPEC,OTC&NUT

毛

5MillionsTransactionsincluded

400

PharmaciesPanel

Datacollectedfrom100Pharmaciesacross

differentregionsinJordan

BackData

24Months

©2025.Allrightsreserved.

NewOfferings

PharmaSellOut

BasedonATCClassification

OTCSellOut

BasedonOTCclassification

NutritionSellOut

OTCclassificationwithmeasureinKilogram

PersonalCareSellOut

Dermocosmetics

PatientCareSellOut

IQVIA

20

Autoimmunediseasesisoneofthekeytherapyareasdrivingthecontinuous

growthofbiologicsasatherapyclass

Howdohealthcarestakeholdersuseautoimmuneprescriptiondatatoday?

K